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Sequencing studies of diffuse large B cell lymphoma (DLBCL) have identified hundreds of
recurrently altered genes. However, it remains largely unknown whether and how these
mutations may contribute to lymphomagenesis, either individually or in combination. Existing
strategies to address this problem predominantly utilize cell lines, which are limited by their
initial characteristics and subsequent adaptions to prolonged in vitro culture. Here, we
describe a co-culture system that enables the ex vivo expansion and viral transduction of
primary human germinal center B cells. Incorporation of CRISPR/Cas9 technology enables
high-throughput functional interrogation of genes recurrently mutated in DLBCL. Using a
backbone of BCL2 with either BCL6 or MYC, we identify co-operating genetic alterations that
promote growth or even full transformation into synthetically engineered DLBCL models. The
resulting tumors can be expanded and sequentially transplanted in vivo, providing a scalable
platform to test putative cancer genes and to create mutation-directed, bespoke lymphoma
models.
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D iffuse large B cell lymphoma (DLBCL) is the most com-mon form of non-Hodgkin lymphoma. Although poten-tially curable with immunochemotherapy, up to 40% of
patients succumb to their disease1. In an attempt to unravel the
biological basis of DLBCL and to identify new therapeutic
opportunities, several groups have recently reported large geno-
mic studies2–4. These highlight the considerable genetic hetero-
geneity of DLBCL and identify hundreds of recurrently mutated
genes, copy number alterations, and structural variants. Clusters
of co-mutated genes suggest the existence of genetic subtypes of
DLBCL that may behave differently when exposed to therapeutic
agents. While the functional and mechanistic consequences of
some of these genetic alterations have been established, for the
majority we have little to no understanding of their contribution
to lymphomagenesis. To translate these genomic findings into
therapeutic progress, it is critical to understand the functional
importance and therapeutic relevance of these genetic alterations,
both individually and in combination.
Existing model systems used for the functional interrogation of
lymphoma genetics consist predominantly of lymphoma cell lines
and genetically modified mice. However, both have limitations;
cell lines were often established from patients with end-stage,
non-nodal or even leukemic phase lymphoma and carry an
extensive and biased mutational repertoire, further selected over
years or even decades of in vitro growth. Genetically engineered
mice, on the other hand, are costly, time-consuming to generate,
and therefore unsuitable for high-throughput or combinatorial
experiments. Furthermore, the genetic requirements for tumor-
igenesis in mice do not always accurately reflect those in
humans5. As such, the development of new, preclinical models of
lymphoma that can capture its considerable genetic diversity has
been identified as a priority area for lymphoma research6.
In common with many of the mature B cell malignancies,
DLBCL is thought to arise from the germinal center (GC) stage of
B cell differentiation7,8. An attractive solution would therefore be
to use primary human GC B cells as a platform for ex vivo genetic
manipulation. Equivalent approaches have proved fruitful for
epithelial malignancies. However, technical difficulties associated
with the ex vivo culture and genetic manipulation of human GC B
cells, including high manipulation-associated cell toxicity and low
transduction efficiency, have obstructed the exploitation of such
models to study lymphoma.
Here, we describe an optimized strategy that facilitates pro-
liferation and highly efficient transduction of non-malignant,
primary, human GC B cells ex vivo. We show that combinations
of oncogenes permit long-term culture in vitro, allowing the
system to be used for high-throughput screening of oncogenes
and tumor suppressors, and for the creation of genetically cus-
tomized human lymphoma models that can be studied in
immunodeficient mice.
Results
Ex vivo growth and transduction of primary human GC B cells.
GC B cells are programmed to undergo apoptosis in the absence
of survival signals from T follicular helper cells and follicular
dendritic cells (FDC). Consistent with this, it is well-established
that GC B cells perish rapidly if cultured unsupported ex vivo9.
Previous attempts to support ex vivo growth of human GC B cells
employed CD40 ligand (CD40lg)-transfected fibroblasts in com-
bination with soluble cytokines including interleukin2 (IL2), IL4,
and IL109,10. Related strategies have used an FDC-like feeder cell,
termed HK, that supported GC survival and allowed short-term
proliferation when combined with CD40lg11. With the increasing
appreciation of the importance of IL21 to GC B cell biology12,13,
later systems have used HK feeder cells combined with CD40lg
and IL21 (ref. 14). However, proliferation of GC B cells in all these
systems was typically limited to a period of up to 10 days9–11,14.
We employed a similar system based upon a freshly established
culture of modified HK cells, termed YK6 that were immortalized
with TERT, P53dd, and CDK4 (Supplementary Fig. 1a). Initial
experiments suggested that membrane-expressed CD40lg in
combination with IL21 facilitated robust stimulation of GC B
cells (Supplementary Fig. 1b). We therefore engineered our
immortalized YK6 cells to express membrane human CD40lg and
to secrete soluble IL21, termed YK6-CD40lg-IL21 (Supplemen-
tary Fig. 1c). We isolated primary GC B cells (CD38+CD20
+CD19+CD10+) from pediatric tonsil tissue (Fig. 1a), which
when grown in co-culture with YK6-CD40lg-IL21 survived
and proliferated vigorously for up to 10 days without a
requirement for any additional cytokines (Fig. 1b, c, Supplemen-
tary Movies 1–5).
In line with previous observations in human B cells15,16 we
were unable to transduce human GC B cells with amphotrophic
or VSV-G pseudotyped virus. Peripheral blood B cells have
previously been transduced using virus pseudotyped with a
Gibbon Ape Leukemia Virus (GaLV) envelope17, the receptor for
which is SLC20A1 (ref. 18). RNA-Seq showed that human GC B
cells express high levels of SLC20A1, but very low levels of the
VSV-G receptor LDLR (Fig. 1d). Thus, we proceeded to test the
GaLV viral envelope to transduce primary GC B cells. To permit
lentiviral transduction, we generated a series of GaLV-MuLV
fusion constructs based on previous reports17,19 (Fig. 1e) and
identified a fusion construct that permitted high efficiency
transduction with both retroviral (Fig. 1f) and lentiviral (Fig. 1g)
constructs of human primary GC B cells cultured on YK6-
CD40lg-IL21 feeders. Interestingly, the GaLV envelopes also
enabled the transduction of primary human DLBCL cells
supported on YK6-CD40lg-IL21 cells (Supplementary Fig. 1d).
Long-term expansion of human GC B cells ex vivo. We pro-
ceeded to use this culture-transduction system to introduce into
human GC B cells oncogenes that are commonly deregulated in
human lymphoma. Out of five genes tested, no single gene was
able to prolong the survival of primary GC B cells cultured in our
system (Fig. 2a, b). However, BCL2 when co-expressed with either
MYC or BCL6 overexpression did lead to long-term expansion
and survival of transduced GC B cells in culture. These cells
continued to expand and proliferate vigorously in culture beyond
100 days. We also tested other transcription factors associated
with the GC reaction, and their lymphoma-associated mutants, in
combination with BCL2 in a pooled, competitive culture. This
showed initial expansion of cells transduced withMEF2B Y69H, a
mutation commonly found in DLBCL and follicular lymphoma20.
However, by day 59, cultures were dominated by BCL6-trans-
duced cells suggesting this as the transcription factor best able to
promote long-term growth of GC B cells ex vivo (Fig. 2c, Sup-
plementary Data 1). Flow cytometry after 10 weeks of culture
showed that cells transduced with BCL2 and BCL6 maintained
expression of surface markers reminiscent of GC B cells including
CD19, CD20, CD22, CD38, CD80, and CD95 (Fig. 2d). Cells
expressed both CD86 and CXCR4 markers, an immunopheno-
type intermediate between light and dark zone GC B cells
(Fig. 2d). Cells transduced with BCL2 and MYC remained viable
and proliferated but downregulated CD20 and CD19, consistent
with differentiation towards plasmablasts (Supplementary
Fig. 1e). The plasma cell marker CD138 was not expressed by
either BCL2/MYC or BCL2/BCL6 transduced cells (Supplemen-
tary Fig. 1f). We compared gene expression profiles of freshly
isolated and transduced GC B cells cultured ex vivo at early
(5 days) and late (10 weeks) time points (Fig. 2e, Supplementary
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Table 1). As anticipated, this showed enrichment of a STAT3-
signature in cultured cells consistent with ongoing
IL21 stimulation. While freshly isolated GC B cells were enriched
for expression of centroblast genes, the cultured and transduced
cells adopted a gene expression profile more similar to that of
centrocytes, consistent with ongoing CD40 stimulation. Impor-
tantly, the centrocyte is the stage of GC differentiation most
similar to DLBCL21. Transcriptome analysis was also compared
with that of six cell lines commonly used as models of GC-derived
lymphomas, including the main subtypes of DLBCL and Burkitt
lymphoma. When compared to a signature of GC-expressed
genes (GCB-1)22, long-term BCL6-transduced cells clustered
more closely with GC B cells than did the cell lines (Fig. 2f,
Supplementary Fig. 1g).
Overall, these results suggest that transduced primary human
GC B cells can be cultured long-term ex vivo, retaining
characteristics of the initial GC B cell that are shared
with DLBCL cells. This represents a valuable model system for
the functional interrogation of genes involved in GC
lymphomagenesis.
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Fig. 1 Ex vivo growth and transduction of primary human GC B cells. a Representative flow cytometry analysis (n > 3) for the expression of GC B cell
markers CD38, CD20, CD19, and CD10 in purified GC B cells from pediatric tonsil tissue. The strategy for negative selection of GC B cells is shown.
b Representative images are shown of YK6 cells, GC B cells alone, or GC B cells cultured on either YK6-CD40lg or YK6-CD40lg-IL21 feeder cells. Scale bar
represents 50 or 100 μm as indicated. Source data are provided as a Source Data file. c Primary human GC B cells were cultured with YK6 control, YK6-
CD40lg, or YK6-CD40lg-IL21 feeder cells. Illustrated is bar graph showing the number of viable cells ( ± s.e.m., n= 5) over four timepoints. Viable cells
were determined by flow cytometry and counting beads. Source data are provided as a Source Data file. d Bar graph showing the relative transcript
expression of SLC20A1 (GaLV receptor) and LDLR (VSV-G receptor) in naïve (n= 1), GC B cells (n= 3), and ABC/GCB DLBCL and Burkitt cell lines (n= 6)
as analyzed by RNA-seq. mRNA expression values were calculated as counts per million reads (CPM). Error bars indicate ± s.e.m. Source data are provided
as a Source Data file. e Schematic of the retroviral and lentiviral MuLV-GaLV fusion envelopes, GaLV_WT, GaLV_MTR, and GaLV_TR. M= transmembrane
region, T= cytoplasmic tail, R= R peptide, SU= surface subunit, TM= transmembrane subunit19. f, g Primary human GC B cells were transduced with a
retroviral control (f) or lentiviral control (g) construct using GaLV-MuLV fusion envelope constructs as well as VSV-G and MuLV. Three days after
transduction, transduction efficiencies in primary human GC B cells were determined by expression of GFP. Error bars indicate ± s.e.m., n= 3. FSC forward
scatter. Source data are provided as a Source Data file
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Screening putative tumor suppressor genes in GC B cells. We
wished to use the system for the high-throughput study of
putative tumor suppressor genes (TSGs) in lymphoma. We
hypothesized that many tumor suppressor pathways are already
inactivated in lymphoma cell lines, and as such, primary GC B
cells should be a more sensitive platform to identify a competitive
growth or survival advantage following TSG inactivation. Robust
expression of Cas9 was achieved using a stable Cas9 retroviral
packaging line (Supplementary Fig. 2a) and initial experiments
confirmed efficient gRNA-directed targeting in primary, human,
GC B cells ex vivo (Supplementary Fig. 2b, c). We therefore
created a lymphoma-focused CRISPR gRNA library composed of
6000 gRNAs targeting a total of 692 genes reported to be mutated
or deleted in human lymphoma, along with 250 non-targeting
control guides. Each gene was targeted by up to nine gRNAs
(Supplementary Fig. 2d) and deep sequencing revealed that 99%
of gRNAs were within four times of the mean frequency (Fig. 3a).
The library was transduced into primary GC cells shortly after
their transduction with BCL2, BCL6, and Cas9 cDNAs (experi-
mental scheme of the CRISPR screening shown in Fig. 3b). Cas9
and gRNA constructs were marked with fluorescent proteins to
allow selection to be visualized by FACS. While Cas9 and gRNA
dual infected cells comprised only 10% of all cells at day 4, this
population expanded to 90% by day 88 of culture (Supplementary
Fig. 2e), suggesting strong selection for one or more of the library
gRNAs. Genomic DNA was sequenced at intervals and a CRISPR
gene score was generated for each gene (Fig. 3b).
Genes that showed the greatest enrichment during culture over
10 weeks included well-established tumor suppressors such as
TP53, CDKN2A, and PTEN (Fig. 3c), thus validating the ability of
our system to detect bona fide TSGs. However, the greatest
enrichment was seen for GNA13 (Fig. 3c), which encodes the G
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Fig. 2 Long-term expansion of human germinal center B cells ex vivo. a Primary human GC B cells were transduced with the indicated oncogenes and
oncogene combinations and cultured separately for up to 120 days. Graph shows calculated theoretical absolute cell numbers (±s.e.m., n= 3). Viable cells
were assessed by trypan blue exclusion. Source data are provided as a Source Data file. b Primary human GC B cells were transduced with different
oncogenes and oncogene combinations and monitored by flow cytometry. Graph shows the change in cell viability assessed by scatter characteristic by
flow cytometry ( ± s.e.m., n= 3). Source data are provided as a Source Data file. c Primary human GC B cells were transduced with BCL2 in combination
with other transcription factors in a pooled, competitive culture. Graph shows relative abundance of transcription factors or their mutant versions over four
different timepoints (n= 3). d Primary human GC B cells were transduced with the oncogenic cocktail BCL2 and BCL6 and cultured to day 73.
Representative flow cytometry analysis (n= 3) for the expression of the GC B cell markers CD38, CD20, CD19, CD80, CD22, CD95, CXCR4, and CD86.
Red histograms show GC B cells compared to primary human naïve B cells (blue). e Heat map of gene expression of freshly isolated GC B cells (n= 3),
transduced GC B cells (BCL2-BCL6, BCL2-MYC) cultured ex vivo for 5 or 73 days (n= 3), plasma cell line (n= 1), naïve B cells (n= 1), and lymphoma cell
lines (TMD8, HBL1, SUDHL4, DOHH2, Mutu, and Raji, n= 6). Illustrated are the selected gene expression signatures—CC-2, GCB-1 as well as BCRUp-2,
MYCUp-2, FL-1, and STAT3Up-1 (Supplementary Table 1). Order of genes in the signatures was determined by hierarchical clustering. f Bar chart showing
the scaled mean expression of the germinal center B cell signature, GCB-1 in freshly isolated GC B cells (n= 3), transduced GC B cells (BCL2-BCL6, BCL2-
MYC) cultured ex vivo for 73 days (n= 3), plasma cell line (n= 1), and lymphoma cell lines (TMD8, HBL1, SUDHL4, DOHH2, Mutu and Raji, n= 6). Error
bars represent the standard error of the mean from independent biological replicates
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protein subunit α13. Indeed, the nine gRNAs targeting GNA13
collectively represented 79% of all reads by day 70 (Supplemen-
tary Fig. 3a). Enrichment for GNA13 was also seen in two further
replicate screens performed in separate tonsil donors (Supple-
mentary Data 2). We saw remarkable consistency of enriched
genes across the three replicate screens, across which the twelve
most enriched genes were GNA13, TP53, CDKN2A, ATRX,
NFKBIA, ZFP36L1, ZNF281, PTEN, FBXO11, FUBP1, S1PR2, and
NFKBIE (Fig. 3d).
To determine whether the oncogenic backbone used would
influence the co-operating TSGs enriched, we repeated the
CRISPR screen using primary GC B cells transduced with BCL2
and MYC. Interestingly, a different profile of TSGs was enriched
on this genetic background with much weaker enrichment of
GNA13 (Supplementary Fig. 3b, Supplementary Data 2). Instead,
some of the most enriched gRNAs in the context of MYC
overexpression targeted members of the ZFP36 family of RNA-
binding proteins, previously demonstrated to oppose cellular
transformation in a mouse model of MYC-induced lymphoma23.
To compare the ability of our culture system to identify TSGs
to that of established cell lines, we performed a parallel screen
using the lymphoma cell line HBL1 (Supplementary Fig. 3c,
Supplementary Data 2) and compared data from recent published
CRISPR screens24 (Supplementary Fig. 3d). In these cell line
experiments, enrichment of gRNAs targeting TSGs was much
more modest. This highlights the unique potential of our primary
GC culture system to identify genetic changes associated with
enhanced growth and survival; a phenotype that is difficult to
identify using heavily mutated cell lines, already optimized for
in vitro growth.
GNA13 depletion enhances survival of GC B cells. The striking
enrichment of GNA13 in all three BCL6-based screens prompted
us to examine this pathway further. Inactivating mutations of
GNA13 are common in DLBCL and BL2,25 but rare in other
forms of cancer, where, in contrast, amplification may be more
common (Supplementary Fig. 3e)26,27. Progressive enrichment
was seen for eight out of nine gRNAs targeting GNA13 over
different timepoints, with equivalent of greater enrichment to that
seen for TP53 and CDKN2A (Fig. 4a). All GNA13 gRNAs led to
effective depletion of GNA13 (Supplementary Fig. 3f), apart from
one which was associated with presumed off-target toxicity and
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Fig. 3 Screening putative tumor suppressor genes in human primary GC B cells. a Illumina sequencing of the lymphoma-focused CRISPR library revealed
that 99% of sequence reads were represented within four times of the mean. Source data are provided as a Source Data file. b Outline of experimental
design and mathematical formulas used. c Rank-ordered depiction of CRISPR gene scores at day 70 (log2 scale) from highest to lowest. Selected tumor
suppressor genes and oncogenes are highlighted in blue and red, respectively. CRISPR gene score for non-targeting control (NTC) (n= 250) is 0.22.
Representative of three experiments. d Bar graph illustrates CRISPR gene scores (log2 scale) for the top 34 enriched genes and 5 most depleted genes
summarized from three independent experiments performed in separate donors. Error bars indicate ± s.e.m. for the three replicate screens. Source data are
provided as a Source Data file
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acts downstream of the G-protein coupled receptors S1PR2 and
P2RY8 and enrichment for both genes was observed in our
screens (Fig. 3c). Mouse knockout studies have suggested that
suppressed activity of this pathway in lymphoma may allow
egress from the GC and increase cell survival secondary to
enhanced AKT activity25,28. In contrast, other studies suggest a
pro-survival effect in DLBCL that is independent of AKT activ-
ity29. We therefore quantified pAKT levels in ex vivo GC B cells
transduced with gRNAs targeting GNA13, PTEN, or non-
targeting controls, and co-cultured on YK6-CD40lg-IL21 feeder
cells (Fig. 4b). Although pAKT was increased in PTEN-depleted
cells, no increase was seen in GNA13-depleted cells. However,
GNA13 depletion did lead to a marked reduction in apoptosis in
cultured primary GC cells (Fig. 4c), but no change in cell pro-
liferation (Supplementary Fig. 3h). This confirms AKT-inde-
pendent, enhanced cell survival as the likely explanation for the
competitive advantage seen following GNA13 depletion in this
culture system.
Mutation-directed, in vivo models of human lymphoma. To
examine the ability of the culture-transduction system to reca-
pitulate lymphomagenesis in vivo, we transduced primary,
human GC B cells with combinations of oncogenic alterations
commonly found in DLBCL (Supplementary Fig. 4a) and injected
them in Matrigel into immunodeficient mice (Fig. 5a). Although
sufficient for long-term, feeder-dependent growth in vitro,
transduction with BCL2 and BCL6, with or without the addition
of a dominant negative TP53 (P53dd)30, was insufficient for
tumor formation in vivo. However, the addition of a fourth
oncogene (BCL6, BCL2, P53dd, and CCND3) led to tumor for-
mation with a median of 112 days (Fig. 5a). The combination of
MYC, BCL2, and P53dd led to tumor formation with a median of
111 days and the combination of MYC, BCL2, and BCL6 resulted
in tumor formation with a median of 108 days. The most potent
combination tested: MYC, BCL2, P53dd, and CCND3 resulted in
tumor formation in all mice within 38 days. Notably, tumors
engrafted with a 100% penetrance and could be derived from
multiple donors, excluding the possibility of donor-derived occult
mutations contributing to transformation. Flow cytometry
showed cells to be strongly positive for markers of all transduced
oncogenes, suggesting potent selection during tumorigenesis
(Fig. 5b).
Histological examination revealed diffuse sheets of medium to
large, atypical lymphoid cells with frequent mitoses, closely
mimicking the appearances of human high-grade B cell
lymphoma (Fig. 5c, Supplementary Figs. 4b and 5). Immuno-
blastic and Burkitt-like appearances were seen in some tumors.
Immunohistochemistry showed expression of the B cell markers
CD19, CD20, CD79A, and PAX5 in the majority of tumors
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Fig. 4 GNA13 revealed as the most potent tumor suppressor gene. a Illustrated is log2 fold enrichment for GNA13, TP53, and CDKN2A normalized to non-
targeting control gRNAs at the indicated timepoints after transduction with the CRISPR library. Circles represent individual gRNAs for the indicated gene.
Data points above the horizontal line are positively enriched. Representative of three experiments in cells from independent donors. Source data are
provided as a Source Data file. b pAKT levels following GNA13 and PTEN deletion in primary human GC B cells was monitored by intracellular FACS staining
for pAKT (S473). A representative example is shown of three PTEN gRNAs (blue)/GNA13 gRNAs (red) against three non-targeting control (NTC) gRNAs
(grey). Bar chart illustrates the mean fluorescence intensity of all gRNAs (GNA13= 6, PTEN= 4, NTC= 3) for the indicated gene (±s.e.m.). The p value was
calculated from t-test. Source data are provided as a Source Data file. c Cell survival following GNA13 and PTEN deletion in primary human GC B cells was
monitored by annexin-V and 7-aminoactinomycin D (7AAD) staining and analyzed by flow cytometry. Bar chart illustrates annexin V-positive cells of all
gRNAs (GNA13= 8, PTEN= 4, NTC= 4) for the indicated gene (±s.e.m.). The p value was calculated by t-test. Source data are provided as a Source
Data file
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in vitro observations where cells transduced with MYC but not
BCL6 downregulated expression of CD20, most MYC-driven
tumors expressed strong surface CD20. The GC marker CD10
was expressed in approximately half of tumors (Fig. 5c,
Supplementary Fig. 4b). Importantly, all tumors were negative
for EBER (ISH) confirming that latent EBV genes did not
contribute to lymphomagenesis in these tumors. Western blot
and RNA-Sequencing confirmed continued expression of the
oncogenic backbone (Supplementary Fig. 6a, b). Harvested tumor
cells could be expanded in vitro and serially retransplanted back
into immunodeficient mice (Supplementary Fig. 6c), thus
functioning as a robust, scalable model system.
To establish the similarity of our synthetic tumors to subsets of
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Fig. 5 Mutation-directed, in vivo models of human lymphoma. a Primary human GC B cells (as well as YK6-CD40lg-IL21 cells) transduced with the
indicated oncogene cocktails were injected subcutaneously into NOD/SCID/gamma mice (n= 3-4 per cohort) and monitored for palpable tumors. Mice
were culled when tumors reached 12 mm in size. Survival of the recipient mice is plotted as a Kaplan–Meier curve. Source data are provided as a Source
Data file. b Cells isolated from tumors were stained for the viral transduction markers CD2 (MYC-t2A-BCL2 or BCL6-t2A-BCL2), Thy1.1 (P53dd), LyT2
(CCND3/Cntrl), and B cell markers CD19, CD10, and CD38 and were analyzed by flow cytometry. A representative example is shown. FSC forward scatter.
c H&E and immunohistochemistry images for the indicated proteins are shown (magnification ×20). Scale bar, 100 μM. Four representative tumors from
mice described in a are shown
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16 synthetic tumors generated from primary GC cells transduced
with different combinations of oncogenes. We compared their
transcriptional profiles to publicly available RNA-Seq data from
DLBCL patients enrolled in the GOYA Trial31, as well as
published RNA-Seq from Burkitt lymphoma patients32. Principal
component analysis was applied to expression of 858 genes2 that
differentiate ABC or GCB DLBCL. While some synthetic tumors
clustered closely with ABC DLBCL, the four synthetic tumors
where the oncogenic backbone included BCL6 were the most
GCB-like (Fig. 6a). Notably, most synthetic tumors sat in a
position intermediate between DLBCL and Burkitt lymphoma, a
finding consistent with the forced expression of MYC. Indeed, we
saw the strong enrichment for two recently described signatures
of MYC-driven lymphoma (double hit signature33 or molecular
high-grade signature34; Fig. 6b, Supplementary Table 1) suggest-
ing that the particular oncogenic backbone used to create these
tumors, generated models with a gene expression profile that
closely approximates double hit lymphoma. We observed strong
NF-kB activity in the cultured B cells, which we attribute to the
CD40 stimulation on feeder cells. However, NF-kB activity was
weaker in synthetic tumors, where CD40 stimulation was not
present (Supplementary Fig. 7a).
To establish the clonality of tumors, we performed deep
sequencing of PCR-amplified immunoglobulin heavy chain
variable gene regions to assess the percentage of unique BCR
sequences in each sample. This revealed that clonality was
increased in primary tumor samples compared to the original
donor cells and was also increased in retransplants compared to
primary tumors (Fig. 7a). BCR network plots showed that tumors
with four oncogenic hits were polyclonal (Fig. 7b). In contrast,
cells transduced with just three oncogenic hits, which formed
tumors with a longer latency, were clonal (Fig. 7b). This suggests
that the combination of four oncogenic events (MYC, BCL2,
CCND3, and P53dd) is by itself sufficient for transformation of
human GC B cell. In contrast, further oncogenic events are
required for lymphomagenesis in cells transduced with just three
of the above constructs. To identify these co-operating oncogenic
events, we performed targeted sequencing using a hematological
malignancy panel of 292 genes. A subclonal NRAS G13A
mutation (VAF 0.03) was detected in the oligoclonal tumor
arising from MYC, BCL2, P53dd transduced cells (Fig. 7c). This
mutation became clonal when retransplanted into secondary
recipients confirming its role in the pathogenesis of those tumors
(Fig. 7c). Mutation at this codon has been reported previously in
DLBCL35 as have other activating mutations of NRAS2. We
observed copy number increase for the experimentally transduced
gene BCL6 (Supplementary Fig. 7b) but saw no evidence of any
significant aneuploidy in any tumor (Supplementary Fig. 7c). In
the polyclonal tumors, subclonal mutations with VAF < 0.05 were
detected in several genes commonly mutated in DLBCL including
a frameshift variant in S1PR2 and missense mutations in GNA13,
NOTCH2, CREBBP, EP300, SOCS1, and BCL6 (Fig. 7c) (Supple-
mentary Data 3). The significance of these mutations to tumor
formation is uncertain; however, some of these genes are typical
targets of aberrant somatic hypermutation suggesting the
possibility of ongoing somatic hypermutation in these lympho-
mas. To investigate this possibility, we analyzed the variable
region sequence of dominant clones detected in the IgH clonality
assay. As expected, given their GC origin, almost all clones
showed evidence of diversification from the germline V gene
sequence (Fig. 7d, e). Importantly, however, clones also showed
evidence of ongoing diversification of the hypervariable regions
(Supplementary Table 2). This suggests that AID-mediated
somatic hypermutation remained active during the process of
tumor formation. In addition, analysis of synthetic tumors
showed varied expression of the IgH constant region genes
across different tumors, with strong expression in many tumors
of IgG and IgA transcripts suggesting that in these tumors, class-
switching had occurred before or during tumor development
(Supplementary Fig. 7d, e).
Overall, the ability of these tumors to closely recapitulate the
appearances of high-grade B cell lymphoma further validates the
biological relevance of this system to the study of human
lymphoma and provides the opportunity to generate mutation-
directed, bespoke in vivo lymphoma models.
Discussion
The plethora of genomic information generated from next-
generation sequencing studies has left us with a need for new
experimental systems in which to study the genetics of human
lymphoma and to decipher these rich data resources. The avail-
ability and suitability of current preclinical models is recognized
as a rate-limiting step in translating genomic knowledge into
patient benefit6. The cell of origin of most aggressive B cell
lymphomas, including DLBCL and BL, is the GC B cell7,8. We
therefore reasoned that non-malignant, human GC B cells should
be the input for a system to create genetically defined models of
human lymphoma. We describe an optimized system for the
culture and transduction of primary, human GC B cells ex vivo.
This relies on the provision of microenvironmental survival sig-
nals common to that of the GC, as well as the overexpression of
combinations of oncogenes common to the pathogenesis of
human lymphoma. In particular, this includes BCL6, a tran-
scription factor central to the GC reaction as well as an estab-
lished oncogene in GC-derived lymphoma. A related strategy has
been employed previously to expand peripheral blood memory B
cells for the purposes of monoclonal antibody engineering36.
Here, we use genetically altered human, primary, GC B cells for
the functional investigation of lymphoma genetics to generate
synthetic, in vivo, human models of lymphoma.
A major advantage of using primary GC B cells over estab-
lished lymphoma cell lines is the ability to investigate defined
genetic alterations on a genetically normal background. In par-
ticular, this provides a sensitive platform for investigating the
ability of specific genetic alterations to increase survival and
proliferation. An enhanced oncogenic phenotype is much harder
to discern in cell lines where the mutational repertoire is likely to
have evolved extensively for optimal in vitro growth. The superior
sensitivity of this system, compared to cell lines, to detect
alterations associated with increased growth or survival is evi-
denced by the strong enrichment for TSGs in our CRISPR screen
when compared to conventional cell lines. Of the 12 most enri-
ched genes (TP53, GNA13, CDKN2A, ATRX, NFKBIA, ZFP36L1,
ZNF281, PTEN, FBXO11, FUBP1, S1PR2, and NFKBIE), the
majority are associated with a tumor suppressor function in
lymphoma, established in the literature either from evidence of
recurrent genetic inactivation or from their ability to inhibit
cancer-promoting pathways2,7,25,37. The next 24 most enriched
genes included TET2, TSC1, GSK3B, RB1, CDKN2B, P2RY8, and
SOCS1, also implicated as TSGs. Thus, the most enriched genes
contained a predominance of recognized TSGs. Although our
experiment was not designed for detection of drop-outs, it is
notable that the two most depleted genes were those targeting
POU2AF1 and MYC, both well-established oncogenes in GC
lymphomas38,39.
Notable absentees from the genes enriching in our CRISPR
screens were the histone modifiers CREBBP, EP300, and KMT2D.
These genes show very frequent inactivating mutations in DLBCL
and follicular lymphoma40–43. These mutations are almost always
clonal, suggesting that they arise at an early stage of lympho-
magenesis, potentially before the GC stage. Interestingly, mouse
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DHIT Down
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Fig. 6 Similarity of synthetic tumors to subsets of bona fide human lymphomas and cell lines. a PCA plots showing human patient samples (GOYA trial, n
= 504; Burkitt lymphoma, n= 28), lymphoma cell lines (Burkitt lymphoma n= 2 (Raji, Mutu), ABC-DLBCL n= 2 (TMD8, HBL1), GCB-DLBCL n= 2
(SUDHL4, DOHH2) and synthetic tumors (BCL6-t2A-BCL2+MYC n= 4, MYC-t2A-BCL2+P53dd n= 3, Retransplant MYC-t2A-BCL2+P53dd n= 4, MYC-
t2A-BCL2+P53dd+CCND3 n= 3, Retransplant MYC-t2A-BCL2+P53dd+CCND3 n= 2). PCA was based on expression of 858 genes differentiating between
ABC- and GCB-DLBCL subtype as described in Schmitz et al.2. b Heat map of gene expression of human patient samples (GOYA trial, n= 504, Burkitt
lymphoma, n= 28), lymphoma cell lines (Burkitt lymphoma n= 2 (Raji, Mutu), ABC-DLBCL n= 2 (TMD8, HBL1), GCB-DLBCL n= 2 (SUDHL4, DOHH2))
and synthetic tumors (BCL6-t2A-BCL2+MYC n= 4, MYC-t2A-BCL2+P53dd n= 3, Retransplant MYC-t2A-BCL2+P53dd n= 4, MYC-t2A-BCL2+P53dd
+CCND3 n= 3, Retransplant MYC-t2A-BCL2+P53dd+CCND3 n= 2). Selected gene signatures are described in Supplementary Table 1. MHG molecular
high grade,34 DHIT double HIT33
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models of Crebbp and Kmt2d deletion show a more pronounced
tumor-promoting phenotype when Cre-mediated knockout is
induced prior to the GC44–48. Therefore, one potential explana-
tion for why these genes do not enrich in our screens is that
during lymphomagenesis, the predominant biological effect of
these mutations is exerted prior to the GC stage. In contrast, the
mutant genes enriched in our screens may reflect those that have
the greatest effect in a GC B cell. Interestingly, some of the top
hits from our screen show similarity to those associated with
transformation of follicular lymphoma into high-grade lym-
phoma (GNA13, CDKN2A, TP53, P2RY8, S1PR2)42. We speculate
that this might be consistent with our screen detecting those
mutations that provide proliferation or survival advantage to an
already “corrupted” GC B cell. In developing lymphoma cells, this
corruption might reflect pre-GC mutations of CREBBP, while in
our screen this oncogenic corruption could be provided by the
forced expression of BCL2, BCL6, or MYC.
The most striking finding from our CRISPR screens was the
potent enrichment of gRNAs targeting GNA13, as well as its
upstream receptors S1PR2 and P2RY8. Inactivating mutations of
GNA13 are common in lymphoma, but rarely seen in other forms
of malignancy. Indeed, amplification is more common in solid
organ cancers, where GNA13 is generally considered to act as an
oncogene49. Thus, its enrichment in our screens reinforces the
specificity of this system to the pathogenesis of GC lymphomas.
Previous mouse studies have proposed roles for GNA13 in the
migration of GC B cells but reached differing conclusions in its
ability to regulate AKT25,28,29. Our data reveal an AKT-
independent effect in the regulation of survival of human GC B
cells, a finding consistent with the greater enrichment of gRNAs
targeting GNA13 over those targeting PTEN in our screens.
The enrichment of GNA13 across experiments performed in
BCL2/BCL6- transduced GC B cells from three separate human
tonsil donors was remarkably consistent. However, when BCL6
was removed from the oncogenic backbone and replaced with
MYC, we no longer saw strong enrichment for depletion of
GNA13. This fits with the distribution of GNA13 mutations in
human DLBCL, which are found predominantly in the EZB
subtype described by Schmitz et al., which expresses the highest
levels of BCL62. Interestingly, some of the most enriched gRNAs
in the context of MYC expression appear to target genes encoding
members of the ZFP36 (Tristetraprolin) family of RNA binding
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Mutation VAF Mutation VAF
GNA13_I34V 0.25 GNA13_I34V 0.06
S1PR2_G314fs 0.03 ND
NOTCH2_S2405G 0.04 NOTCH2_S2405G 0.02
SOCS1_V13I/T15P 0.14/0.13 ND





BCL6-t2A-BCL2 + MYC 
Primary tumor Retransplant
Oncogene cocktail
MYC-t2A-BCL2 + P53dd + CCND3
NRAS_G13A 0.03MYC-t2A-BCL2 + P53dd
Fig. 7 Human GC B cells form tumors in immunodeficient mice with ongoing somatic hypermutation. a Boxplot shows unique BCR counts (FR1) of primary
tumors, retransplant, and healthy donor cells. Source data are provided as a Source Data file. b Representative BCR network plots of deep sequenced PCR
amplified immunoglobulin variable gene regions from primary tumor samples (n= 8) and retransplants (n= 4). Each vertex represents a unique sequence,
where relative vertex size is proportional to the number of identical reads. Edges join vertices that differ by single-nucleotide non-indel differences
and clusters are collections of related, connected vertices. c Table shows selected mutations and their relationship in primary and retransplant tumors.
d, e Unrooted phylogenetic trees of representative clonal expansions observed across samples. Each vertex is a unique BCR and branch lengths are
estimated by maximum parsimony
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proteins. This finding is consistent with existing biological
knowledge of these proteins, which negatively regulate cell cycle37
and have been demonstrated to oppose cellular transformation in
a mouse model of MYC-induced lymphoma23. These findings
highlight the potential to introduce further changes to the back-
bone combination in order to study synergy between different
sets of cancer genes. We envisage future studies may also remove
or replace components of the feeder-based stimulation, for
instance to identify factors promoting cytokine-independent
growth. The selective pressure imposed could be further altered
by the use of pharmacological inhibitors of specific pathways.
Future studies might also employ mutant open reading frame
(mORF) screens or targeted CRISPR gene editing to introduce
specific mutations into endogenous loci.
The relevance of this culture system to the pathogenesis of
human lymphoma is underscored most strongly by the ability to
recapitulate the appearances of human high-grade B cell lym-
phoma when cells are engrafted into immunodeficient mice.
Notably, our data reveal that the transformation of a human GC
B cell appears to require a minimum of four oncogenic hits. The
oncogenic backbones used in these experiments employed com-
binations of BCL2, BCL6, MYC, TP53, and CCND3, widely
accepted as common lymphoma driver genes. RNA-Seq revealed
how the oncogenic backbone affected the transcriptional profile,
with tumors appearing more GCB-like when BCL6 was included
in the oncogenic backbone. Consistent with the enforced
expression of BCL2 and MYC, we saw strong enrichment for
signatures of double hit lymphoma33,34, a subtype of lymphoma
characterized by translocation of both MYC and BCL2 and
associated with a particularly poor clinical outcome. We antici-
pate that future studies will further alter the oncogenic backbone
to model specific disease subtypes for functional analysis and
preclinical drug testing.
The complex genetic heterogeneity of human lymphoma is
becoming increasingly evident2–4. It is clear that the repertoire of
available cell lines does not adequately represent each of the many
molecular subtypes predicted from the analysis of sequencing
studies. Therefore, the ability to generate mutation-directed
tumors in vivo provides an attractive route for patient-
personalized preclinical models. A particular advantage over
tumor-derived xenograft models is the ability to create paired,
syngeneic controls; tumors that are genetically identical other
than the presence or absence of a specific mutation. Similar
approaches to culture and manipulate human primary cells are
proving successful for some solid organ malignancies. However
technical limitations have precluded this in B cell lymphoma. We
present an extensively optimized, yet inexpensive strategy to
employ primary, human, GC B cells for the investigation of
lymphoma genomics and to generate bespoke, in vivo models of
human lymphoma. This addresses an important bottleneck in
translating lymphoma genomic findings into functional under-
standing that can drive improved patient outcomes and perso-
nalized therapy.
Methods
Plasmid construction. The CDS for human gene sequences were cloned into the
pBMN-IRES-LyT2 retroviral vector (kind gift of Dr. Louis Staudt, National Cancer
Institute, USA) to express CCND3, BCL6, or IL21 using synthetic double-stranded
DNA from IDT with Gibson Assembly (NEB). For CCND3, a mutation in the
threonine residue at Threonine 283 (T283A) was included to enhance protein
expression32. BCL2, CD40L, or MYC were cloned into MSCV-based vectors using
synthetic double-stranded DNA and Gibson Assembly. For overexpression of
multiple human genes, CDS sequences were cloned into the MSCV-IRES-huDC2
vector (kind gift of Dr Martin Turner, the Babraham Institute, UK) with the t2A
peptides linking genes, such as BCL6-t2A-BCL2, MYC-t2A-BCL2, and P53dd-t2A-
BCL2 or an additional p2A peptide when linking three genes such as P53dd-p2A-
CDK4_R24C-t2A-BCL2. pBABE-hygro-hTERT was a gift from Bob Weinberg
(Addgene plasmid # 1773; http://n2t.net/addgene:1773; RRID:Addgene_1773)50.
P53dd and CDK4_R24C were cloned into MSCV-IRES-Thy1.1 DEST vector using
synthetic double-stranded DNA from IDT with Gibson Assembly. MSCV-IRES-
Thy1.1 DEST was a gift from Anjana Rao (Addgene plasmid # 17442; http://n2t.
net/addgene:17442; RRID:Addgene_17442)51.
The MSCV-CAS9-2A-BFP construct was modified from Addgene plasmid
#65655 by excision of the IRES/Puro elements and insertion of a 2A-BFP sequence
using dsDNA and Gibson assembly. MSCV_Cas9_puro was a gift from
Christopher Vakoc (Addgene plasmid # 65655; http://n2t.net/addgene: 65655;
RRID:Addgene_65655)52.
The custom CRISPR library and single gRNAs were cloned into pKLV2-
U6gRNA-Bbsi-PGK-GFP, which was modified from pKLV2-U6gRNA5(Empty)-
PGKBFP2AGFP-W. pKLV2-U6gRNA5(Empty)-PGKBFP2AGFP-W was a gift
from Kosuke Yusa (Addgene plasmid # 67979; http://n2t.net/addgene: 67979;
RRID:Addgene_67979)53. Pooled oligos for construction of the lymphoma-focused
CRISPR library were obtained from TWIST Bioscience and oligos for single gRNAs
were obtained from IDT. To make the GaLV-MuLV fusion envelope constructs,
pHIT12354 (kind gift of Prof Markus Muschen, City of Hope, Los Angeles, CA)
containing the retroviral ecotropic envelope, human cytomegalovirus immediate-
early promoter and the origin of replication from simian virus 40 was used as the
backbone. The viral envelopes GaLV_WT, GaLV_MTR, and GaLV_TR were based
on the SEATO strain of GaLV (NP_056791). GaLV_MTR and GaLV_TR contain
the 3′ GaLV envelope sequence replaced by the MuLV transmembrane region,
cytoplasmic region, and R peptide region and the MuLV cytoplasmic region and R
peptide region, respectively19. All sequences were purchased from IDT as synthetic
double-stranded DNA and inserted by Gibson assembly. All plasmids were verified
by capillary sequencing.
Cell culture. Cell lines HBL1, BJAB, U2932, TMD8, SUDHL4, DOHH2, Raji,
Mutu (all kind gifts from Dr Louis Staudt, National Cancer Institute, USA) and
NCIH929 (ATCC CRL-9068) were cultured in Roswell Park Memorial Institute
medium (RPMI-1640, Invitrogen, Carlsbad, CA). Primary human GC B cells were
cultured in Advanced Roswell Park Memorial Institute medium (Advanced RPMI-
1640; Invitrogen, Carlsbad, CA) with GlutaMAX containing 20% FBS, 100 IU/ml
penicillin and 100 µg/ml streptomycin and kept at 37 °C in a humidified incubator
(5% CO2 and 95% atmosphere).
Lenti-X 293 T Cell Line (Clontech Laboratories, 632180) were cultured in
Dulbecco’s modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA)
containing 10% FBS, 100 IU/ml penicillin, and 100 µg/ml streptomycin and kept at
37 °C in a humidified incubator (5% CO2 and 95% atmosphere). All cell lines used
in this study were confirmed to be free from mycoplasma contamination and
identity was verified using a 16-amplicon multiplexed copy number variant
fingerprinting assay24.
Construction of YK6-CD40Lg-IL21 feeder line. Discarded human tonsil tissue
was obtained after a routine tonsillectomy and handled in accordance with an IRB-
approved protocol (2013-0864) at the Asian Medical Center, Seoul, South Korea.
The requirement for informed consent was waived by the institutional review
board because there was no additional risk to the subjects and all identities were
anonymized and completely delinked from unique identifiers. FDC were extracted
from tonsils following an established protocol for the creation of HK FDC-like
feeder cells11. Following mechanical disruption and enzymatic digestion, the
released cells were collected and subjected to Ficoll gradient centrifugation for 20
min at 2200 r.p.m. The interface layer that contains FDC was then collected. The
cells were resuspended in RPMI 1640 medium and centrifuged at 200 r.p.m. for 10
min at 4 °C over a discontinuous gradient of 7.5% and 3% bovine serum albumin
(BSA; A9418; Sigma-Aldrich, St. Louis, MO, US). FDC-enriched fractions were
collected from the interface. Cells were washed with HBSS and cultured on tissue
culture dishes. Cells isolated and culture after these procedures initially contained
large adherent cells with attached lymphocytes. Non-adherent cells were removed
and adherent cells replenished with fresh medium every 3–4 days. Adherent cells
were trypsinized when confluence was attained. Because of the limited growth in
culture, FDC-like cells were immortalized (now termed YK6) through retroviral
transduction with pBABE_TERT.Hygro, P53DD_Thy1.1 and
CDK4_R24C_Thy1.1. Immortalized YK6 cells were further transduced with
hCD40Lg-Puro and IL21-LyT2.
Purification of human GC B cells. Fresh, tonsil tissue was sourced from the
Addenbrooke’s ENT Department, Cambridge with written informed consent of the
patient/parent/guardian and processed directly to preserve viability. Ethical
approval for the use of human tissue was granted by the Health Research Authority
Cambridgeshire Research Ethics Committee (REC no. 07/MRE05/44). GC B cells
were purified using the human B cell negative selection isolation Kit II (MACS,
Miltenyi Biotec) as per the manufacturer’s instructions. The protocol was modified
to include negative selection antibodies IgD-BIOT (IADB6; SouthernBiotech 9030-
08, 1:100) and CD44-BIOT (F10-44-2; SouthernBiotech 9400-08, 1:100) to remove
naïve and memory B cells55. Cells were stained for CD38 (HB7; BioLegend #12-
0388-42, 1:500), CD20 (2H7; BioLegend #17-0209-41, 1:500), CD19 (HIB19;
BioLegend #302223, 1:500), and CD10 (97C5; MiltenyiBiotec, 130-093-450, 1:500)
to confirm enrichment of GC B cells. B cell genomic DNA was screened for EBV
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status using a quantitative real-time PCR (qPCR) assay56 and cells from EBV-
positive were discarded. qPCR Primer sequences are as follows:
EBV F QP1L 5′-GCCGGTGTGTTCGTATATGG-3′
EBV R QP2L 5′-CAAAACCTCAGCAAATATATGAG-3′
GC B cells were plated onto irradiated YK6-CD40lg-IL21 and split every
2–3 days. Fresh YK6-CD40lg-IL21 cells (irradiated 30 Gy) were added with each
split. Primary human GC B cells were cultured in Advanced Roswell Park
Memorial Institute medium (Advanced RPMI-1640, Invitrogen, Carlsbad, CA)
with GlutaMAX containing 20% FBS, 100 IU/ml penicillin, and 100 µg/ml
streptomycin and kept at 37 °C in a humidified incubator (5% CO2 and 95%
atmosphere).
Retroviral and lentiviral production. Retroviral packaging plasmids pHIT60
(kind gift of Dr. Louis Staudt, National Cancer Institute, USA) and GaLV WT were
used as follows: 1 μg pHIT60 (gag-pol), 1 μg GaLV WT (envelope), and 4 μg of a
retroviral construct was used to transfect each 10 cm2 dish of HEK-293T, after
mixing with 1 ml of Opti-MEM media (Invitrogen) and 18 μl of TransIT-293
(Mirus). For lentivirus transfections, packaging plasmids pCMVDeltaR8.91 and
GaLV MTR were used as follows: 8.3 μg pCMVDeltaR8.91 (gag-pol), 2.8 μg GaLV
MTR (envelope), and 11 μg of a lentiviral construct per 10 cm2 dish, incubated with
1 ml of Opti-MEM media (Invitrogen) and 33 μl of TransIT-293 (Mirus). For
infecting cell lines, pMD2.G (VSV-G envelope) was used instead of GaLV MTR.
pMD2.G was a gift from Didier Trono (Addgene plasmid # 12259; http://n2t.net/
addgene:12259; RRID:Addgene_12259). The packaging line Lenti-X 293T Cell Line
(Clontech Laboratories) was used for all transfections. After 36–48 h, the virus
supernatant was filtered through a 0.45 μM filter. If needed, media was replenished
and harvested again at 16 h later. For retroviral/lentiviral transduction, 1–2 × 106
target cells were resuspended with viral supernatant and infected by centrifugation
(1500 × g, 90 min at 32 °C) with the addition of 10 μg/ml Polybrene (INSIGHT
Biotechnology) and 25 μM HEPES (ThermoFisher) in 12- or 24-well plates. Viral
supernatant was replaced with fresh media immediately after centrifugation for
retroviral infection or after >4 h if transducing lentiviral constructs. Cells were
maintained at 37 °C with 5% CO2 for 2–4 days before analyzing by FACS.
Mouse experiments. Cultured human GC B cells were injected subcutaneously
into the left flank of NSG mice (Jackson laboratories). Up to 10 × 106 cells were
washed and resuspended with Matrigel (Corning) in a 1:1 ratio. Mice were culled
when tumors reached 12 mm in size. Tumors were processed immediately after
harvest and analyzed by flow cytometry and histology. This research has been
regulated under the Animals (Scientific Procedures) Act 1986 Amendment Reg-
ulations 2012 following ethical review by the University of Cambridge Animal
Welfare and Ethical Review Body (AWERB-PPL number P846C00DB).
Generation of lymphoma-focused CRISPR guideRNA library. gRNA sequences
were based upon two recent genome-wide libraries53,57. Position one of 20 set to G
for all gRNAs. Appropriate overlapping sequences (underlined) for Gibson
Assembly into the gRNA expression plasmid pKLV2_U6gRNA_Bbsi_PGK_GFP
(modified from Addgene #67979) were appended to all 6000 gRNAs. A 70-mer
oligo pool was purchased from TWIST BIOSCIENCE as follows:
5′-TATCTTGTGGAAAGGACGAAACACCG-N19-GTTTAAGAGCTATG
CTGGAAACAGC-3′
N19 represents each of the 6000 gRNA sequences. The single-stranded oligo
pool was converted to double-stranded DNA by PCR amplification using Q5 Hot
Start High-Fidelity 2X Master Mix (NEB) with 3 ng of the oligo pool as a template
and primers (Zhang_F and Zhang_R_modified). The following PCR conditions
were used as follows: 95 °C for 2 min, 10 cycles of 95 °C for 20 s, 60 °C for 20 s, and









The 150 bp PCR product was gel purified from a 2% Agarose gel using the Gel
Extraction kit (Qiagen) and eluted in 20 μl EB Buffer. Four Gibson Assembly
reactions were performed using 14.4 ng of the purified 150 bp fragment and 200 ng
of the BbsI-digested pKLV2_U6gRNA_Bbsi_PGK_GFP with Gibson HiFi DNA
Assembly Master Mix (NEB). Gibson Assembly reactions were pooled and
column-purified using MinElute PCR purification kit (Qiagen). Eight
electroporations were performed using 1 μl of the purified Gibson reaction and 20
μl of Endura Competent Cells (Lucigen). The mixture was transferred to a 0.1 cm
cuvette and electroporated at 1.8 kV. Immediately after, 2 ml of prewarmed SOC
media was added to each reaction and placed on a shaker at 37 °C for 1 h. The
electroporated cells were combined and plated onto 16 24.5 cm2 LB+ ampicillin
agar plates using ColiRollers Plating Beads (Merck Millipore). Plates were left at 30
°C overnight and plasmid DNA was purified using a Plasmid Maxi kit (Qiagen).
Transduction of CRISPR library and generation of gRNA sequencing libraries.
GC B cells were transduced with the backbone oncogene cocktail and Cas9-BFP
retrovirus until Cas9-BFP reached between 50% and 80%. The number of cells
transduced with gRNA library was adjusted to take account of the percentage of
Cas9-expressing cells and target MOI of 0.3 in order to maintain representation of
>1000× the size of the library. Four days after transduction, BFP and GFP
expression was analyzed by flow cytometry and at each harvest timepoint going
forward. A minimum of 1000× representation was maintained at each passaging
step. Cells were harvested every 14 days. Genomic DNA extraction was conducted
as described previously58 which is as follows: 600 μl Lysis Buffer and 15 μl Pro-
teinase K were used to re-suspend cells and left at 65 °C for 15 min. Depending on
cell pellet, Lysis Buffer and Proteinase K volume was scaled up and incubated until
pellet completely lysed. Isopropanol was used to precipitate genomic DNA and
further re-suspended in TE Buffer. Illumina sequencing was performed as
follows53,59. For sequencing of all gRNAs in the CRISPR library, primers (gLibrary-
HiSeq_50bp-SE-U1 and −L1) were used to amplify the region containing the







For this PCR, it is crucial to use sufficient genomic DNA to capture every gRNA
in the cell population. This depends on the complexity of populations to be
analyzed. For human cells, 106 cells contain around 6.6 μg of genomic DNA
(assuming normal copy number). Therefore, the number of cells (millions)
harvested × 6.6 μg will correspond to the amount of genomic DNA needed in the
first PCR. For example, if a cell population was 30% double positive for CAS9-BFP
and CRISPR library-GFP, then 20 × 106 cells were harvested to achieve 1000×
coverage (6000 guides × 1000 coverage/0.3). In this case 131 μg (20 × 6.6) of
genomic DNA was used in the first PCR, with a maximum of 10 μg per 50 μl
reaction. Therefore, 13 independent PCR reactions were performed using 10 μg of
genomic DNA per reaction with Q5 Hot Start High-Fidelity 2x Master Mix. The
following PCR conditions were used: 98 °C for 30 s, 20–24 cycles of 95 °C for 10 s,
61 °C for 15 s, and 72 °C for 20 s, and the final extension, 72 °C for 2 min. Five
microliters from each PCR reaction were run on 2% Agarose gel and PCR was run
for a few more cycles if there was no PCR product or PCR bands were still faint.
Next, 10 μl from each individual PCR reaction per sample was taken, pooled and
purified using QIAquick PCR Purification Kit (Qiagen). DNA was eluted in 50 μl
EB buffer (Qiagen) and concentration was quantified on the nanodrop. In the
second PCR, nextgen sequencing adaptors (P5, P7) compatible with Illumina’s
HiSeq4000 and a barcode were added. One nanogram of the purified PCR product
was used with NEBNext Q5 Hot Start HiFi PCR Master Mix with the following
conditions: 98 °C for 30 s, 9–12 cycles of 98 °C for 10 s, 65 °C for 75 s and the final
extension, 65 °C for 5 min. Forward primer named Indexing Adapter PE 1.0 and
different reverse indexing primers (iPCRtagT1-56) were used in this second PCR.
A different reverse indexing primer was used for each sample. Primer sequences are
as follows:
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Five microliters from each PCR reaction were run on 2% agarose gel and
checked for visible PCR bands. The PCR products were purified with Agencourt
AMPure XP beads in a PCR-product-to-bead ratio of 1:0.7 and eluted in 30 μl EB
Buffer (Qiagen). The purified libraries were quantified, pooled, and sequenced on
Illumina HiSeq4000 by 50-bp single-end sequencing. Two custom sequencing
primers were used here: iPCRtagseq which reads through the indices and U6-
Illumina-seq2 which reads through the gRNA sequence. Enriched gRNAs were
defined based upon enrichment relative to the plasmid pool counts. Purified
libraries were quantified, pooled, and sequenced on Illumina HiSeq4000 by 50-bp
single-end sequencing with the following primers:
iPCRtagseq 5′-AAGAGCGGTTCAGCAGGAATGCCGAGACCGATCTC-3′
U6-Illumina-seq2 5′-TCTTCCGATCTCTTGTGGAAAGGACGAAACACCG-3′
Computational analysis of CRISPR screens. Raw reads were normalized to a






denotes the raw sequencing reads of gRNA i of gene g at time t in replicate r. For
each gRNA the Z-score of log2 fold change between plasmid library and late










Finally, CRISPR scoreg, which represents the magnitude and direction of a fitness







where Lg denotes the number of sgRNA of gene g in replicate r and R is the number
of available replicates.
RNA-sequencing. Total RNA from cells was extracted using NucleoSPIN RNA
from Macherey-Nagel and cDNA was produced from 500 ng of total RNA using
qScriptTM cDNA SuperMix (Quanta Biosciences). RNA-seq library was prepared
using the NEBNext Poly (A) mRNA Magnetic Isolation Module (E7490) and
NEBNext Ultra Directional RNA Library Prep Kit for Illumina (E7420) according
to the manufacturer’s instructions. NEBNext Multiplex Oligos for Illumina (E7500)
was used for indexing and sequenced on a HiSeq4000 by 50-bp single-end
sequencing. RNA-Seq were mapped to the hg38/GRCh38 reference human genome
using splice-aware aligner STAR 2.5.3a60 in two pass-mode. The genome index was
built with GENCODE v.28 comprehensive gene annotation set. Uniquely mapped
reads were assigned to genes with RSubread package61 allowing for assignment of a
read to more than one overlapping features. At least 25 of overlapped bases were
required to assign a read to a gene. Genes with low counts were filtered out with a
threshold of minimum 128 counts in at least 25% of samples. Gene expression
measurements were TPM normalized. To remove effect of technical variation
between different RNA-Seq runs, variance stabilizing transformation was applied
as implemented in the DESeq2 (ref. 62) package.
Barcoded overexpression experiments. The CDS for human gene sequences
(BCL6 WT, BCL6_G559R, BCL6_H641R, BCL6_R585W, BCL6_P586A, IRF8 WT,
IRF8_N87Y, IRF8_T80A, IRF8_380_stop, IRF8_S55A, MEF2B WT,
MEF2B_D83V, MEF2b Y69H) were cloned into barcoded pBMN-IRES-LyT2
retroviral vector using NEBuilder® HiFi DNA Assembly. Primary human GC B
cells were retrovirally transduced with BCL2, followed by infection with barcoded
overexpression genes and pooled 4 days after transduction, and then grown in
competitive culture. Genomic DNA was collected at day 4 and approximately every
14 days after. Genomic DNA extraction was conducted as described in the
Methods section “Transduction of CRISPR library and generation of gRNA
sequencing libraries”. Individual indices (Truseq Small RNA Index Sequences)
were added using Q5 Hot Start High-Fidelity 2x Master Mix. The purified library
was quantified, pooled and sequenced on Illumina MiSeq by 50-bp single-end
sequencing.
Computational analysis of barcoded overexpression experiments. Relative






where Nictr denotes the raw sequencing counts of clone i of constructs c at time t in







where Lct denotes the number of clones of construct c at time t and R is the number
of available replicates.
BCR amplification. PCR amplification of DNA from synthetic lymphoma tumors
(100 ng input) was performed with 1 μl of JH reverse primer (10 μM) and 1 μl of
FR1 forward primer set pools (10 μM per primer, provided by Sigma Aldrich) using
25 μl of Q5 Hot Start Master Mix (2X) (New England Biolabs) for a total volume
reaction of 50 μl. The following PCR program was used: 5 min at 95 °C; three cycles
of 5 s at 98 °C and 2min at 72 °C; three cycles of 5 s at 98 °C, 10 s at 65 °C, and 2
min at 72 °C; and 25 cycles of 20 s at 98 °C, 30 s at 60 °C, and 2 min at 72 °C; with a
final extension cycle of 7 min at 72 °C on a Mastercycler nexus Thermocycler
(Eppendorf) (modified from ref. 63). MiSeq libraries were generated using KAPA
Hyper Prep Kit (KAPA Biosystems) incorporating KAPA Dual-Indexed Adapter
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for Illumina MiSeq platforms following the manufacturer instructions. MiSeq reads
were filtered for base quality (median Phred score > 32) using the QUASR program
(http://sourceforge.net/projects/quaasi/) and for length (300 bp paired-end)64. The
computational pipeline MRD Assessment and Retrieval Code in Python
(MRDARCY) was then used to analyze BCRs, followed by secondary rearrange-
ment analysis in which the relative frequencies of each IgHV gene were determined
by BLAST using the ImMunoGeneTics (IMGT) reference gene database. The








High-throughput sequencing and analysis of heavy chain immunoglobulin.
Deep sequencing of PCR amplified immunoglobulin heavy chain variable gene
regions and BCR network generation algorithm and network properties were
performed as follows63. Each vertex represents a unique sequence, where relative
vertex size is proportional to the number of identical reads. Edges join vertices that
differ by single-nucleotide non-indel differences and clusters are collections of
related, connected vertices. Ig gene usages and sequence annotation were per-
formed in IMGT V-QUEST, where repertoire differences were performed by
custom scripts in Python.
For the visual representations of the BCR repertoires, BCR network
subsampling was performed using the cluster-enforced linkage sampling (CC)
method to preserve the overall clonal structure. Briefly, the CC algorithm employs
three steps to account for loss of connectivity between vertices in clusters during
sampling:
Vertex selection: Vertices were reselected until the number of desired clusters in
the original network G are represented.
Cluster-vertex migration: For each cluster in the original network which
contains more than one vertex that was sampled, vertices were reselected such that
the cluster connectivity is retained in the sampled network.
Induced graph formation: Graph induction selects the set of edges (Es) to be
included in the sampled graph. Total graph induction is used in CC, selecting all
edges incident on the sampled vertices are included in the sampled graph.
This process was repeated 20 times, and the subsample that most closely
represented the true (unsampled) maximum cluster size was retained and plotted
IGHV gene editing analyses were performed in a similar manner to. For all
BCRs, stem regions were identified (defined as N-IgHD-N-IgHJ regions starting 3
bp downstream of the IgHV gene boundary). The number of unique BCR
sequences sharing stem regions but with different IgHV gene usage (>95%
difference in sequence identity in the IgHV region) and with different 5′ of the
junctional region (defined as IgHV(last 3pb)-N-IgHD-N-IgHJ) was determined
and compared to the total number of unique BCRs to give the percentage IgHV
replacement. Sequences with joining regions (N-IgHD-N-IgHJ regions) shorter
than eight nucleotides were excluded from this percentage due to potential of
germline encoded receptors.
Mutation analysis. To identify somatic mutations across synthetic lymphoma
tumors a hybrid-capture platform was used with a bait set58 (SureSelect, Agilent,
UK, ELID # 0731661) of 292 genes frequently mutated in hematological malig-
nancies. After hybridization-based sequence enrichment (SureSelectHSXT, Agilent),
high-throughput sequencing was performed on the Illumina HiSeq 4000 platform.
Sequencing data alignment. DNA sequencing reads were aligned to the
GRCh37d5 according to the workflow described at Samtools webpage (http://www.
htslib.org/workflow/) as follows: For mapping the data to a given reference genome
BWA-MEM65 0.7.17, followed by Samtools66 1.9 for cleaning up read pairing
information and flags on SAM records. For improvement of the mapped data
Broad’s GATK67 Realigner 3.8.1 was used in order to reduce the number of mis-
calls of INDELs, followed by Picard 2.18.25 (http://broadinstitute.github.io/picard)
for identifying duplicates.
Variant calling for substitutions and indels. Single base substitutions and short
insertions and deletions were called using GATK67 4.1 Mutect2 based on the
tutorials available at Broad Institute website (https://gatkforums.broadinstitute.org/
gatk/discussion/11136/how-to-call-somatic-mutations-using-gatk4-mutect2). The
mutant variants were annotated using Variant Effect Predictor68 from ENSEMBL
version 95.
Copy number analysis. Copy number analysis was performed using GeneCN
(https://github.com/wwcrc/geneCN).
FACS (fluorescence-activated cell sorting). Cells were stained with fluorophore-
labeled antibodies in 2% BSA in PBS according to the manufacturer’s instructions.
The stained/or unstained cells were analyzed on the LSRII (BD). For cell counting,
CountBright Absolute Counting Beads (ThermoFisher) were used according to the
manufacturer’s instructions and analyzed on the LSRII (BD). For dead cell apop-
tosis analysis, APC-conjugated Annexin V/Dead Cell Apoptosis Kit (BioLegend
640930) was used for the detection of apoptotic cells according to the manu-
facturer’s instructions. Externalization of phosphatidylserine (Annexin V, APC
Conjugate; BioLegend, 1:20) and DNA content (7-AAD; BioLegend,1:20) were
measured and gating on all cells was used for further analysis. Cell cycle analysis
was performed using the Vybrant® DyeCycle™ Ruby Stain (ThermoFisher V10309,
1:500, Final stain concentration 5 μM) according to the manufacturer’s instruc-
tions. Cells were treated with Nocodazole (1 μg/ml) 24 h prior to staining. Stained
cells were analyzed by gating on cells in the G2 phase using FlowJo software.
Intracellular staining of phosphorylated AKT was performed as follows: Cell
suspension and pre-warmed Fixation Buffer (BD Cytofix) was gently mixed in a
1:1 ratio and incubated at 37 oC for 15 min. Cell suspension was pelleted and
washed with PBS twice at 350g for 5 min. Ice-cold True-Phos perm buffer (BD
Cytofix) was added dropwise to the cell pellet while vortexing, followed by
incubation at −20 oC for at least 60 min. Cells were further washed twice and
resuspended in FACS buffer (PBS+ 2% FBS) containing the appropriate
antibody at a dilution of 1:50 (Phospho-Akt Ser473, Cell Signaling, #11962).
After staining for 30 min, cells were washed and resuspended in FACS buffer
followed by analysis on the LSRII (BD).
The following antibodies were used: CD38 (HB7, #12-0388-42, 1:500), CD20
(2H7, #17-0209-41, 1:500), CD19 (HIB19, #302223/302211/302205, 1:500), CD10
(97C5, MiltenyiBiotec, 130-093-450, 1:500), CD2 (RPA-2.10, #300207/300235,
1:500), CD90.1 Thy1.1 (OX-7, #202529, 1:500), CD154 (24-31, #310805, 1:500),
CD8a (53-6.7, #100712, 1:500), CD22 (HIB22, #302510, 1:500), CD80 (2D10,
#305219, 1:500), CD95 (DX2, #305629, 1:500), CD86 (IT2.2, #305419, 1:500),
CXCR4 (12G5, #306505, 1:500), IgM (MHM-88, #314506, 1:500) and IgG
(#H10164, 1:500). All antibodies were purchased from BioLegend if not otherwise
stated. Gating strategies can be found in Supplementary Fig. 8.
Western blotting. Western blotting was performed as follows:58 CelLytic buffer
(Sigma) supplemented with 1% protease inhibitor cocktail (Roche), 1% phospha-
tase inhibitor cocktail (Calbiochem Millipore), and 1 mM PMSF (Life Technolo-
gies) was used to lyse cells followed by loading the same amount of protein per
sample on NuPAGE (Invitrogen) 4–12% Bis-Tris gradient gels and were further
transferred on PVDF membranes (Invitrogen). Primary antibodies were used with
the HRP immunodetection system (Life Technologies/Millipore). The following
antibodies were used: Beta-actin (13E5; Cell Signaling Technology #4970, 1:10000),
GNA13 (EPR5436; Abcam ab128900, 1:1000), BCL-6 (D65C10; Cell Signaling
Technology #5650, 1:500), c-MYC (N-262; Santa Cruz sc-764, 1:500), and BCL-2
(7/Bcl-2; Becton Dickinson Biosciences 610539, 1:500). Uncropped western blots
can be found in the Source Data file.
Patient samples. Gene expression data (RNA-Seq) from DLBCL and Burkitt
lymphoma patients were downloaded from Gene Expression Omnibus (GEO),
accession number: GSE125966 (ref. 31) and from Sequence Read Archive (SRA),
accession number: SRA048058 (ref. 32). Datasets were TMM normalized and
adjusted for batch effect with ComBat function from sva package (3.30.1)69.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Gene expression data has been uploaded to the EGA database under the accession
number EGAS00001003560. Deep sequencing of PCR amplified immunoglobulin heavy
chain variable gene regions has been submitted to the SRA under the BioProject ID:
PRJNA551148 [https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA551148]. All
the other data supporting the findings of this study are available within the article and its
supplementary information files and from the corresponding author upon reasonable
request. A reporting summary for this article is available as a Supplementary
Information file.
Received: 15 April 2019; Accepted: 11 September 2019;
References
1. Bowzyk Al-Naeeb, A., Ajithkumar, T., Behan, S. & Hodson, D. J. Non-
Hodgkin lymphoma. BMJ 362, k3204 (2018).
2. Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma.
N. Engl. J. Med. 378, 1396–1407 (2018).
3. Reddy, A. et al. Genetic and functional drivers of diffuse large B cell
lymphoma. Cell 171, 481–494 e415 (2017).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12494-x
14 NATURE COMMUNICATIONS |         (2019) 10:4543 | https://doi.org/10.1038/s41467-019-12494-x | www.nature.com/naturecommunications
4. Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are
associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24,
679–690 (2018).
5. Hahn, W. C. et al. Creation of human tumour cells with defined genetic
elements. Nature 400, 464–468 (1999).
6. Weinstock, D. M. et al. A roadmap for discovery and translation in
lymphoma. Blood 125, 2175–2177 (2015).
7. Shaffer, A. L. III, Young, R. M. & Staudt, L. M. Pathogenesis of human B cell
lymphomas. Annu. Rev. Immunol. 30, 565–610 (2012).
8. Basso, K. & Dalla-Favera, R. Germinal centres and B cell lymphomagenesis.
Nat. Rev. Immunol. 15, 172–184 (2015).
9. Pound, J. D. & Gordon, J. Maintenance of human germinal center B cells
in vitro. Blood 89, 919–928 (1997).
10. Arpin, C. et al. Generation of memory B cells and plasma cells in vitro. Science
268, 720–722 (1995).
11. Kim, H. S., Zhang, X., Klyushnenkova, E. & Choi, Y. S. Stimulation of
germinal center B lymphocyte proliferation by an FDC-like cell line, HK. J.
Immunol. 155, 1101–1109 (1995).
12. Linterman, M. A. et al. IL-21 acts directly on B cells to regulate Bcl-6
expression and germinal center responses. J. Exp. Med. 207, 353–363
(2010).
13. Zotos, D. et al. IL-21 regulates germinal center B cell differentiation and
proliferation through a B cell-intrinsic mechanism. J. Exp. Med. 207, 365–378
(2010).
14. Ding, B. B., Bi, E., Chen, H., Yu, J. J. & Ye, B. H. I. L.-21 and CD40L
synergistically promote plasma cell differentiation through upregulation of
Blimp-1 in human B cells. J. Immunol. 190, 1827–1836 (2013).
15. Janssens, W. et al. Efficiency of onco-retroviral and lentiviral gene transfer
into primary mouse and human B-lymphocytes is pseudotype dependent.
Hum. Gene Ther. 14, 263–276 (2003).
16. Serafini, M., Naldini, L. & Introna, M. Molecular evidence of inefficient
transduction of proliferating human B lymphocytes by VSV-pseudotyped
HIV-1-derived lentivectors. Virology 325, 413–424 (2004).
17. Mock, U., Thiele, R., Uhde, A., Fehse, B. & Horn, S. Efficient lentiviral
transduction and transgene expression in primary human B cells. Hum. Gene
Ther. Methods 23, 408–415 (2012).
18. Overbaugh, J., Miller, A. D. & Eiden, M. V. Receptors and entry cofactors for
retroviruses include single and multiple transmembrane-spanning proteins as
well as newly described glycophosphatidylinositol-anchored and secreted
proteins. Microbiol. Mol. Biol. Rev. 65, 371–389 (2001).
19. Christodoulopoulos, I. & Cannon, P. M. Sequences in the cytoplasmic tail of
the gibbon ape leukemia virus envelope protein that prevent its incorporation
into lentivirus vectors. J. Virol. 75, 4129–4138 (2001).
20. Ying, C. Y. et al. MEF2B mutations lead to deregulated expression of the
oncogene BCL6 in diffuse large B cell lymphoma. Nat. Immunol. 14,
1084–1092 (2013).
21. Victora, G. D. et al. Identification of human germinal center light and dark
zone cells and their relationship to human B-cell lymphomas. Blood 120,
2240–2248 (2012).
22. Dave, S. S. et al. Molecular diagnosis of Burkitt’s lymphoma. N. Engl. J. Med.
354, 2431–2442 (2006).
23. Rounbehler, R. J. et al. Tristetraprolin impairs myc-induced lymphoma and
abolishes the malignant state. Cell 150, 563–574 (2012).
24. Phelan, J. D. et al. A multiprotein supercomplex controlling oncogenic
signalling in lymphoma. Nature 560, 387–391 (2018).
25. Muppidi, J. R. et al. Loss of signalling via Galpha13 in germinal centre B-cell-
derived lymphoma. Nature 516, 254–258 (2014).
26. Cerami, E. et al. The cBio cancer genomics portal: an open platform for
exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404
(2012).
27. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
28. Healy, J. A. et al. GNA13 loss in germinal center B cells leads to impaired
apoptosis and promotes lymphoma in vivo. Blood 127, 2723–2731 (2016).
29. Flori, M. et al. The hematopoietic oncoprotein FOXP1 promotes tumor cell
survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. Blood
127, 1438–1448 (2016).
30. Shaulian, E., Zauberman, A., Ginsberg, D. & Oren, M. Identification of a
minimal transforming domain of p53: negative dominance through
abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12, 5581–5592
(1992).
31. McCord, R. et al. PD-L1 and tumor-associated macrophages in de novo
DLBCL. Blood Adv. 3, 531–540 (2019).
32. Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from
structural and functional genomics. Nature 490, 116–120 (2012).
33. Ennishi, D. et al. Double-hit gene expression signature defines a distinct
subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J. Clin.
Oncol. 37, 190–201 (2019).
34. Sha, C. et al. Molecular high-grade B-cell lymphoma: defining a poor-risk
group that requires different approaches to therapy. J. Clin. Oncol. 37,
202–212 (2019).
35. Morin, R. D. et al. Mutational and structural analysis of diffuse large B-cell
lymphoma using whole-genome sequencing. Blood 122, 1256–1265 (2013).
36. Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing
B cell receptor-positive human memory B cells by genetic programming. Nat.
Med. 16, 123–128 (2010).
37. Galloway, A. et al. RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell
quiescence. Science 352, 453–459 (2016).
38. Hodson, D. J. et al. Regulation of normal B-cell differentiation and malignant
B-cell survival by OCT2. Proc. Natl. Acad. Sci. USA 113, E2039–E2046 (2016).
39. Bisso, A., Sabo, A. & Amati, B. MYC in germinal center-derived lymphomas:
Mechanisms and therapeutic opportunities. Immunol. Rev. 288, 178–197
(2019).
40. Pasqualucci, L. et al. Genetics of follicular lymphoma transformation. Cell Rep.
6, 130–140 (2014).
41. Okosun, J. et al. Integrated genomic analysis identifies recurrent mutations
and evolution patterns driving the initiation and progression of follicular
lymphoma. Nat. Genet. 46, 176–181 (2014).
42. Kridel, R. et al. Histological transformation and progression in follicular
lymphoma: a clonal evolution study. PLoS Med. 13, e1002197 (2016).
43. Green, M. R. et al. Hierarchy in somatic mutations arising during genomic
evolution and progression of follicular lymphoma. Blood 121, 1604–1611
(2013).
44. Zhang, J. et al. The CREBBP Acetyltransferase is a haploinsufficient tumor
suppressor in b-cell lymphoma. Cancer Discov. 7, 322–337 (2017).
45. Garcia-Ramirez, I. et al. Crebbp loss cooperates with Bcl2 overexpression to
promote lymphoma in mice. Blood 129, 2645–2656 (2017).
46. Horton, S. J. et al. Early loss of Crebbp confers malignant stem cell properties
on lymphoid progenitors. Nat. Cell Biol. 19, 1093–1104 (2017).
47. Zhang, J. et al. Disruption of KMT2D perturbs germinal center B cell
development and promotes lymphomagenesis. Nat. Med. 21, 1190–1198
(2015).
48. Ortega-Molina, A. et al. The histone lysine methyltransferase KMT2D sustains
a gene expression program that represses B cell lymphoma development. Nat.
Med. 21, 1199–1208 (2015).
49. Zhang, Z. et al. GNA13 promotes tumor growth and angiogenesis by
upregulating CXC chemokines via the NF-kappaB signaling pathway in
colorectal cancer cells. Cancer Med. 7, 5611–5620 (2018).
50. Counter, C. M. et al. Dissociation among in vitro telomerase activity, telomere
maintenance, and cellular immortalization. Proc. Natl. Acad. Sci. USA 95,
14723–14728 (1998).
51. Wu, Y. et al. FOXP3 controls regulatory T cell function through cooperation
with NFAT. Cell 126, 375–387 (2006).
52. Shi, J. et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of
protein domains. Nat. Biotechnol. 33, 661–667 (2015).
53. Tzelepis, K. et al. A CRISPR dropout screen identifies genetic vulnerabilities
and therapeutic targets in acute myeloid leukemia. Cell Rep. 17, 1193–1205
(2016).
54. Shojaee, S. et al. Erk negative feedback control enables pre-B cell
transformation and represents a therapeutic target in acute lymphoblastic
leukemia. Cancer Cell 28, 114–128 (2015).
55. Kremmidiotis, G. & Zola, H. Changes in CD44 expression during B cell
differentiation in the human tonsil. Cell Immunol. 161, 147–157 (1995).
56. Stevens, S. J. et al. Monitoring of Epstein-Barr virus DNA load in peripheral
blood by quantitative competitive PCR. J. Clin. Microbiol. 37, 2852–2857
(1999).
57. Doench, J. G. et al. Optimized sgRNA design to maximize activity and
minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184–191
(2016).
58. Caeser, R. et al. Targeting MEK in vemurafenib-resistant hairy cell leukemia.
Leukemia 33, 541–545 (2019).
59. Koike-Yusa, H., Li, Y., Tan, E. P., Velasco-Herrera Mdel, C. & Yusa, K.
Genome-wide recessive genetic screening in mammalian cells with a lentiviral
CRISPR-guide RNA library. Nat. Biotechnol. 32, 267–273 (2014).
60. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29,
15–21 (2013).
61. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose
program for assigning sequence reads to genomic features. Bioinformatics 30,
923–930 (2014).
62. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
63. Bashford-Rogers, R. J. et al. Network properties derived from deep sequencing
of human B-cell receptor repertoires delineate B-cell populations. Genome Res.
23, 1874–1884 (2013).
64. Bashford-Rogers, R. J. et al. Capturing needles in haystacks: a comparison of
B-cell receptor sequencing methods. BMC Immunol. 15, 29 (2014).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12494-x ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:4543 | https://doi.org/10.1038/s41467-019-12494-x | www.nature.com/naturecommunications 15
65. Li, H. Aligning sequence reads, clone sequences and assembly contigs with
BWA-MEM. Preprint at arXiv:13033997v2 [q-bioGN] (2013).
66. Li, H. et al. The Sequence Alignment/Map format and SAMtools.
Bioinformatics 25, 2078–2079 (2009).
67. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework
for analyzing next-generation DNA sequencing data. Genome Res. 20,
1297–1303 (2010).
68. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17,
122 (2016).
69. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva
package for removing batch effects and other unwanted variation in high-
throughput experiments. Bioinformatics 28, 882–883 (2012).
Acknowledgements
D.H. was supported by a Clinician Scientist Fellowship from the Medical Research
Council (MR/M008584/1). Research in the Hodson laboratory is supported by the Kay
Kendall Leukaemia Fund, The Addenbrooke’s Charitable Trust, Cancer Research UK,
and a research scholarship from Gilead Sciences. The Hodson laboratory receives core
funding fromWellcome and MRC to the Wellcome-MRC Cambridge Stem Cell Institute.
We thank Alice Mitchell and the ENT Department at Addenbrooke’s Hospital, Cam-
bridge for their assistance in the collection of primary tonsil tissue. We are grateful to
Joanna Baxter and Cambridge Blood and Stem Cell Bank for collection and storage of
primary tonsils samples and to the staff of the Central Biomedical Services for animal
housing and care. We thank Craig McDonald for technical assistance with video
microscopy, Mairi Shepherd for graphical illustrations and Martin Dyer, Ingo Ring-
shausen, and Reuben Tooze for critical reading of the manuscript.
Author contributions
R.C. designed and performed the experiments and analyzed data. M.D.R., J.G., M.L.C.,
R.F., Z.U., H.R., and A.M. performed experiments. J.K. analyzed RNA-seq experiments.
J.M.L.D. analyzed CRISPR screen experiments. S.L.C. analyzed copy number alterations.
R.J.M.B. analyzed whole genome sequencing and clonality experiments. H.E. provided
immunohistochemistry support. H.K.P. and C.S.P. provided YK-feeder cells. P.A.B., G.V.
and B.J.P.H. provided conceptual input to the study. D.J.H. designed the experiments,
provided clinical expertise, directed the research, and wrote the manuscript with con-
tributions from R.C.
Competing interests
D.J.H.: Research funding from Gilead Sciences; Consultancy for Karus Therapeutics.
P.A.B.: consultancy for Karus Therapeutics (Oxford, UK), OncoDNA (Gosselies,
Belgium), and Everything Genetic (London, UK). The remaining authors declare no
competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
019-12494-x.
Correspondence and requests for materials should be addressed to D.J.H.
Peer review information Nature Communications thanks the anonymous reviewer(s) for
their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12494-x
16 NATURE COMMUNICATIONS |         (2019) 10:4543 | https://doi.org/10.1038/s41467-019-12494-x | www.nature.com/naturecommunications
